Autonomous Agentic AI Systems for Pharmaceutical Drug Discovery: A Multi-Agent Framework for Molecular Design and Optimization

Contemporary drug discovery represents an extraordinarily complex and capital-intensive scientific challenge, characterized by development timelines extending 10-15 years and clinical failure rates surpassing 90%. Existing computational frameworks operate within fragmented ecosystems that demand persistent human oversight and require laborious coordination across heterogeneous analytical workflows. This research introduces a autonomous agentic artificial intelligence platform engineered to transform pharmaceutical research through intelligent multi-agent orchestration. The developed architecture coordinates specialized computational agents that function synergistically across molecular design, property prediction , synthetic pathway optimization, and multi-criteria decision-making processes. Through integration of advanced transformer-based molecular representation learning, multi-agent reinforcement learning paradigms, and privacy-preserving federated learning infrastructures, the system enables autonomous model collaboration while maintaining strict data sovereignty. This research provides foundational theoretical frameworks, defines modular architectural specifications, and validates implementation protocols for next-generation autonomous drug discovery platforms. The framework addresses critical limitations in current methodologies through autonomous reasoning capabilities, adaptive exploration strategies, and coordinated optimization across conflicting research priorities. The resulting platform represents a significant leap toward fully autonomous pharmaceutical discovery pipelines, demonstrating potential for dramatic timeline compression while enhancing therapeutic development success rates.

当代药物研发是一项极为复杂且资本密集的科学挑战，其研发周期长达10至15年，临床失败率更是超过90%。现有计算框架运行于碎片化的生态系统中，不仅需要持续的人工监管，还需在异构分析流程间开展繁重的协调工作。本研究提出一款自主智能体人工智能（autonomous agentic artificial intelligence）平台，旨在通过智能多智能体协同编排革新药物研发范式。该架构可协调专用计算智能体，使其在分子设计、属性预测、合成路径优化以及多准则决策等流程中协同发挥作用。通过集成先进的基于Transformer的分子表征学习、多智能体强化学习范式以及隐私保护型联邦学习基础设施，该系统可实现模型的自主协作，同时严格保障数据主权。本研究为下一代自主药物研发平台提供了基础理论框架，明确了模块化架构规范，并验证了其实现协议。该框架通过自主推理能力、自适应探索策略，以及针对冲突研究优先级的协同优化，解决了当前方法中的关键局限。最终打造的平台向着全自主化药物研发管线迈出了重要一步，展现出大幅压缩研发周期、提升疗法开发成功率的巨大潜力。